Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.25 USD | +1.47% | +3.23% | -44.91% |
04-30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.91% | 2.81B | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating